ARBUTUS BIOPHARMA CORP (ABUS) Stock Analyst Ratings
USA - NASDAQ:ABUS - CA03879J1003 - Common Stock
4.45 USD
-0.09 (-1.98%)
4.45 USD
0 (0%)
ChartMill assigns a Buy % Consensus number of 82% to ABUS. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 5.36. This target is 20.34% above the current price.
ABUS was analyzed by 10 analysts. The buy percentage consensus is at 82. So analysts seem to be very confident about ABUS.
In the previous month the buy percentage consensus was at a similar level.
ABUS was analyzed by 10 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-11-14 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-08-11 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-03-28 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-01-21 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-20 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-11-18 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-07 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-06 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-09-05 | Jefferies | Maintains | Buy -> Buy |
| 2024-08-02 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2024-06-07 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-06-06 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-06-05 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-05-03 | Chardan Capital | Reiterate | Buy -> Buy |
| 2024-04-04 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2024-03-01 | Chardan Capital | Reiterate | Buy -> Buy |
| 2024-03-01 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-09-12 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-08-04 | Chardan Capital | Reiterate | Buy -> Buy |
| 2023-08-04 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-07-11 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-07-06 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2023-06-22 | Chardan Capital | Reiterate | Buy -> Buy |
| 2023-06-22 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-05-05 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-04-28 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-04-05 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-03-29 | JMP Securities | Reiterate | Market Outperform |
| 2023-03-20 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-03-03 | Chardan Capital | Reiterate | Buy |
ARBUTUS BIOPHARMA CORP / ABUS FAQ
What is the price target for ABUS stock?
10 analysts have analysed ABUS and the average price target is 5.36 USD. This implies a price increase of 20.34% is expected in the next year compared to the current price of 4.45.
How do analysts rate ARBUTUS BIOPHARMA CORP (ABUS)?
The consensus rating for ARBUTUS BIOPHARMA CORP (ABUS) is 82 / 100 . This indicates that analysts generally have a positive outlook on the stock.
How many analysts cover ARBUTUS BIOPHARMA CORP (ABUS) stock?
The number of analysts covering ARBUTUS BIOPHARMA CORP (ABUS) is 10.